20.12.2023 - Mithra Completes Pediatric Study of ESTELLE in Adolescent Patients Important milestone for Mithra’s commitment to bring benefits of ESTELLE to more womenPotential EMA approval in pediatric population could lead to six-month extension of the . Seite 1
18.12.2023 - Mithra Receives Positive DSMB Opinion on DONESTA European Phase 3 Trial The DSMB recommends continuing the phase 3 trial in Europe following regular safety assessmentThe menopause phase 3 program has previously reported positive top-line data; . Seite 1
17.10.2023 - Mithra’s Board of Directors to propose the removal of its request for change of the remuneration policy at the Special General Meeting Liege, Belgium, 17 October 2023 – 7:00 CEST – Mithra (Euronext Brussels: MITRA) (the “Company”), a company .
10.10.2023 - Mithra to hold joint symposium with partner Gedeon Richter on 11 OctoberFour leading experts will outline why estrogens are critical in contraception and postmenopausal symptomsData show promising safety and efficacy features of E4, key ingredient . Seite 1
05.10.2023 - Mithra Provides an Update in the Context of Recent Market Developments Financial results show Mithra has solid financial foundation and multiple options to financeShareholder meetings called to consider routine matters of business Liege, Belgium, . Seite 1